Test Price
2,800 AED✅ Home Collection Available
GP1BA Gene Bernard-Soulier Syndrome Type A2 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين GP1BA لمتلازمة برنارد-سولييه من النوع A2 بتقنية التسلسل الجيني المتقدم (NGS) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 9.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold‑Chain Home Collection and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
خلاصة تنفيذية
يوفر هذا الاختبار الجيني المتقدم تشخيصًا دقيقًا لمتلازمة برنارد-سولييه من النوع A2 عبر تقنية التسلسل الجيني المتقدم (NGS)، معتمدًا من هيئة الصحة بدبي لعام 2026. يُنفذ في مختبر حاصل على شهادة الآيزو 9001:2015 مع خدمة سحب عينات منزلية فاخرة. نضمن دقة تشخيصية بنسبة 99.9% ودعمًا سريريًا بعد النتيجة.
Overview
This test utilises high‑resolution Next‑Generation Sequencing (NGS) to analyse the entire coding region of the GP1BA gene, the sole gene associated with Bernard‑Soulier syndrome type A2. It delivers definitive molecular confirmation for patients with unexplained macrothrombocytopenia and bleeding tendencies, allowing precise genetic counselling and future therapeutic planning.
يستخدم هذا الاختبار تقنية التسلسل الجيني المتقدم (NGS) لتحليل كامل الجين GP1BA المرتبط بمتلازمة برنارد-سولييه من النوع A2. يوفر تأكيدًا جزيئيًا قاطعًا لحالات نقص الصفيحات الكبيرة مع أعراض نزفية غير مفسرة، مما يُمكّن من الاستشارة الوراثية الدقيقة والتخطيط للمستقبل.
| Parameter | Our Test (NGS + Sanger) | Standard Single‑Gene Sanger |
|---|---|---|
| Methodology | Targeted capture NGS with bioinformatic coverage ≥100×; all pathogenic variants confirmed by orthogonal Sanger sequencing. | Capillary Sanger sequencing of individual exons (may miss large deletions/duplications). |
| Turnaround Time | 3–4 Weeks (includes confirmatory Sanger). | 4–6 Weeks for full gene coverage. |
| Detection Rate | ~99% for single‑nucleotide variants, indels, and exon‑level copy number changes. | ~95% for SNVs; miss large rearrangements. |
| Clinical Utility | Gold‑standard for definitive diagnosis, family cascade screening, and pre‑implantation genetics. | Suitable only when a known familial variant is already characterised. |
Physician Insight & Safety Protocol
“As a clinician, I recognise the anxiety that surrounds a potential lifelong bleeding disorder. This NGS test provides definitive molecular clarity for the GP1BA gene, but it must be interpreted alongside your personal and family bleeding history. I strongly recommend a consultation with a haematologist and a certified genetic counsellor to translate the result into a personalised care plan.”
— Dr. PRABHAKAR REDDY, DHA License 61713011
Medication Warning
Do not discontinue prescribed medication without consulting your doctor.
Safety Exclusions & Red Flags
- Exclusion: Active, uncontrolled bleeding or severe thrombocytopenia (platelets <30×10⁹/L) – medical stabilisation required prior to elective genetic sampling.
- ER Red Flags: Spontaneous intracranial or gastrointestinal bleeding, sudden large‑area ecchymoses, prolonged (>30 minutes) epistaxis, or heavy menstrual haemorrhage with haemodynamic instability. Seek emergency care immediately; this test is not for acute diagnosis.
Patient FAQ & Clinical Guidance
1. What is the turnaround time for the GP1BA NGS test in the UAE?
Answer: The typical turnaround time is 3 to 4 weeks from sample receipt, including confirmation by Sanger sequencing for any detected variants.
2. Is this test covered by UAE health insurance?
Answer: Many UAE insurance plans cover this genetic test when medically necessary; we provide direct billing verification via WhatsApp.
3. How is the sample collected for the GP1BA gene test?
Answer: We offer convenient home blood collection or you can provide a DNA sample via FTA card without venipuncture.
UAE Regulatory Compliance & Accreditation
This laboratory operates under the applicable UAE Federal Decree‑Law No. 41 of 2024 (Art. 87) governing genetic data privacy, the UAE Child Protection Law (CDS 2026) mandating guardian consent for minors, and the UAE Personal Data Protection Law (PDPL). All services are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and align with DHA/MOHAP standards. Pre‑ genetic counselling and a pedigree chart are mandatory components; results are subject to strict data privacy protocols.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians